Heron's Sustol Faces Competition With Narrower Label Than Expected

Heron Therapeutics gained approval of its chemotherapy-induced nausea and vomiting drug Sustol (granisetron), but the company faces stiff competition and postmarketing requirements. Analysts, nonetheless, think the product has a bright future on the US market.

Approved

The long, tormented regulatory journey Heron Therapeutics Inc. has been on over the past nearly seven years with its chemotherapy-induced nausea and vomiting (CINV) drug Sustol (granisetron) has finally come to a somewhat successful end, with the FDA granting its go-ahead for the product to be marketed in the US, although not for the broad use the company had sought.

The product moves Heron from a research and development company to a commercial enterprise. The question now is whether Heron...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip